These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 3022584)

  • 21. Side effects and metabolic effects of converting enzyme inhibitors.
    Omae T; Kawano Y; Yoshida K
    Clin Exp Hypertens A; 1987; 9(2-3):635-42. PubMed ID: 3038427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enalapril versus captopril: a double-blind multicentre comparison in essential hypertension.
    Rumboldt Z; Marinković M; Drinovec J
    Int J Clin Pharmacol Res; 1988; 8(3):181-8. PubMed ID: 2841251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors.
    Weber MA
    Am J Med; 1988 Apr; 84(4A):16-23. PubMed ID: 3064605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of enalapril in moderate to severe essential hypertension.
    Walker JF; Kulaga SF; Kramsch DM
    J Hypertens Suppl; 1984 Dec; 2(2):S107-11. PubMed ID: 6100871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Captopril and enalapril in the treatment of renal hypertension].
    Hasanagić H; Djukanović Lj; Subotić Z; Nesić V; Cavrić G
    Srp Arh Celok Lek; 1990; 118(7-8):285-90. PubMed ID: 2097777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
    Lewis RA; Baker KM; Ayers CR; Weaver BA; Lehman MR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S12-5. PubMed ID: 2580164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerance and safety of enalapril.
    McFate Smith W; Davies RO; Gabriel MA; Kramsch DM; Moncloa F; Rush JE; Walker JF
    Br J Clin Pharmacol; 1984; 18 Suppl 2(Suppl 2):249S-253S, 255S. PubMed ID: 6099740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerability of long term therapy with enalapril maleate in patients resistant to other therapies and intolerant to captopril.
    Rucinska EJ; Small R; Mulcahy WS; Snyder DL; Rodel PV; Rush JE; Smith RD; Walker JF; Irvin JD
    Med Toxicol Adverse Drug Exp; 1989; 4(2):144-52. PubMed ID: 2541310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with converting-enzyme inhibitors in hypertension.
    Weber MA
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):45-51. PubMed ID: 3037889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Captopril and enalapril: angiotensin-converting enzyme inhibitors.
    Allen TA; Wilke WL; Fettman MJ
    J Am Vet Med Assoc; 1987 Jan; 190(1):94-6. PubMed ID: 3028998
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enalapril: a new angiotensin converting enzyme inhibitor.
    Cleary JD; Taylor JW
    Drug Intell Clin Pharm; 1986 Mar; 20(3):177-86. PubMed ID: 3007062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Materson BJ
    Compr Ther; 1983 Oct; 9(10):14-20. PubMed ID: 6196149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of inhibition of angiotensin I conversion by three converting enzyme inhibitors in rats.
    Takata Y; Di Nicolantonio R; Hutchinson JS
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():129-34. PubMed ID: 6183035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Undesirable effects and interaction to angiotensin converting enzyme inhibitors therapy].
    Ionescu SD; Sandru V; Leuciuc E; Manea P; Burdujan A; Tovarniţchi S; Cosovanu A
    Rev Med Chir Soc Med Nat Iasi; 2002; 106(1):128-31. PubMed ID: 12635373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disappearance of captopril-induced taste disturbance after substitution with angiotensin-converting-enzyme inhibitor HOE 498.
    Mauersberger H; Witte PU
    Lancet; 1985 Mar; 1(8427):517-8. PubMed ID: 2857878
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and efficacy of enalapril. Summing up the evidence.
    Dollery CT
    J Hypertens Suppl; 1983 Oct; 1(1):155-7. PubMed ID: 6100605
    [No Abstract]   [Full Text] [Related]  

  • 38. Differences in the effects of angiotensin converting enzyme inhibitors with or without a thiol group in chronic renal failure in rats.
    Ohishi A; Suzuki H; Nakamoto H; Katsumata H; Sakaguchi H; Saruta T
    Clin Sci (Lond); 1989 Apr; 76(4):353-6. PubMed ID: 2540931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of captopril and enalapril on electroencephalogram and cognitive performance in healthy volunteers.
    Ebert U; Kirch W
    Eur J Clin Pharmacol; 1999 Jun; 55(4):255-7. PubMed ID: 10424316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group.
    Testa MA; Anderson RB; Nackley JF; Hollenberg NK
    N Engl J Med; 1993 Apr; 328(13):907-13. PubMed ID: 8446137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.